Shopping Cart
- Remove All
Your shopping cart is currently empty
Oclacitinib maleate
🥰Excellent
Catalog No. T6914Cas No. 1640292-55-2
Alias PF-03394197 maleate, PF-03394197
Oclacitinib maleate (PF-03394197 maleate) is a novel inhibitor of JAK family members, with IC50 values ranging from 10 to 99 nM, and JAK1-dependent cytokines, with IC50 ranging from 36 to 249 nM, while not inhibiting a panel of 38 non-JAK kinases.
Oclacitinib maleate
🥰Excellent
Purity: 99.17%
Catalog No. T6914Alias PF-03394197 maleate, PF-03394197Cas No. 1640292-55-2
Oclacitinib maleate (PF-03394197 maleate) is a novel inhibitor of JAK family members, with IC50 values ranging from 10 to 99 nM, and JAK1-dependent cytokines, with IC50 ranging from 36 to 249 nM, while not inhibiting a panel of 38 non-JAK kinases.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $33 | In Stock | |
| 2 mg | $46 | In Stock | |
| 5 mg | $72 | In Stock | |
| 10 mg | $101 | In Stock | |
| 25 mg | $178 | In Stock | |
| 50 mg | $286 | In Stock | |
| 100 mg | $480 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $78 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "Oclacitinib maleate"
Deucravacitinib
BMS-986165
T146871609392-27-9
Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable, allosteric TYK2 inhibitor for the treatment of autoimmune diseases. It blocks receptor-mediated Tyk2 activation by stabilizing the regulatory JH2 domain, inhibiting IL-12/23 and type I IFN pathways. It selectively binds to the TYK2 pseudokinase (JH2) domain with an IC50 of 1.0 nM.
- $64
Size
QTY
GSK 3 Inhibitor IX
Cited
MLS 2052, GSK 3 IX, BIO, 6-bromoindirubin-3-oxime, 6-Bromoindirubin-3'-oxime, 6-BIO
T1917667463-62-9
GSK 3 Inhibitor IX (6-BIO) is a selective reversible, ATP-competitive inhibitor of GSK-3α/β and CDK1-cyclinB complex. It inhibits (GSK-3α/β)/CDK1/CDK5 activity with IC50 values of 5 nM/320 nM/83 nM, respectively.
- $37
Size
QTY
CitedTofacitinib Cited
Tasocitinib, CP-690550
T6321477600-75-2
Tofacitinib (Tasocitinib) is a Janus kinase inhibitor that inhibits JAK3/2/1 (IC50=1/20/112 nM) and is orally active. Tofacitinib is used for the treatment of moderate to severe rheumatoid arthritis.
- $30
Size
QTY
CitedRuxolitinib phosphate Cited
Ruxolitinib (INCB-18424) phosphate, INCB018424 phosphate, INCB018424, INC424, INC 424 phosphate
T30431092939-17-7
Ruxolitinib phosphate (INCB18424 phosphate) is a JAK1/2 inhibitor with IC50 of 3.3 nM/2.8 nM. Its selectivity for JAK1/2 is more than 130 times that of JAK3.
- $44
Size
QTY
CitedRO8191 Cited
RO4948191, CDM-3008
T22142691868-88-9
RO8191 (CDM-3008) (CDM-3008) is an agonist of interferon (IFN) receptor.
- $38
Size
QTY
CitedCEP-33779
Cited
CEP33779
T61221257704-57-6
CEP-33779 is a novel and selective inhibitor of JAK2 with an IC50 of 1.8±0.6 nM.
- $38
Size
QTY
CitedFedratinib Cited
TG-101348, SAR 302503
T1995936091-26-8
Fedratinib (TG-101348) (TG101348) is an ATP-competitive inhibitor of JAK2 (IC50: 3 nM) with significantly less potent activity against JAK3.
- $45
Size
QTY
CitedGefitinib Cited
ZD1839
T1181184475-35-2
Gefitinib (ZD1839) is an EGFR first-generation inhibitor with oral activity that inhibits the EGFR 19 Del and L858R mutations. Gefitinib has antitumor activity and is used for the treatment of EGFR-mutated non-small-cell lung cancers. Gefitinib administration RESULTS in the development of the EGFR C797S resistance mutation.
- $50
Size
QTY
CitedTofacitinib Citrate
Tofacitinib (CP-690550) Citrate, Tasocitinib citrate, CP-690550 citrate
T2398540737-29-9
Tofacitinib Citrate (CP-690550 citrate) is a a potent, cell-permeable inhibitor of JAK1/2/3 (IC50s: 1/20/112 nM).
- $32
Size
QTY
Delgocitinib
JTE-052, Corectim(Delgocitinib)
T150961263774-59-9
Delgocitinib (JTE-052) is a specific JAK (Janus kinase) inhibitor with IC50 values of 2.8, 2.6, 13, and 58 nM for JAK1, JAK2, JAK3, and Tyk2 respectively. Delgocitinib is involved in various inflammatory and autoimmune diseases through JAK-dependent cytokines and can effectively suppress multiple cytokine signaling while inhibiting itching caused by cytokines. It is widely used to treat various inflammatory diseases, including autoimmune diseases and hypersensitivity reactions.
- $172
Size
QTY
Ibrutinib Cited
PCI-32765
T1835936563-96-1
Ibrutinib (PCI-32765) is an irreversible inhibitor of BTK (IC50: 0.5 nM) that selectively blocks B cell activation.
- $36
Size
QTY
CitedSelect Batch
Purity:99.17%
Contact us for more batch information
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.Product Introduction
Bioactivity
Chemical Properties
| Description | Oclacitinib maleate (PF-03394197 maleate) is a novel inhibitor of JAK family members, with IC50 values ranging from 10 to 99 nM, and JAK1-dependent cytokines, with IC50 ranging from 36 to 249 nM, while not inhibiting a panel of 38 non-JAK kinases. |
| Targets&IC50 | JAK:10 to 99 nM, JAK1-dependent:36 to 249 nM |
| In vitro | Oclacitinib inhibits JAK family members by 50% at concentrations ranging from 10 to 99 nM and does not inhibit a panel of 38 non-JAK kinases. Oclacitinib is most potent at inhibiting JAK1. Oclacitinib also inhibits the function of JAK1-dependent cytokines involved in allergy and inflammation as well as pruritus. Oclacitinib has minimal effects on cytokines which does not activate the JAK1 enzyme in cells[1]. |
| In vivo | Oclacitinib administered orally at a dose of 0.4–0.6 mg/kg twice daily is safe and efficacious in controlling the pruritus associated with allergic dermatitis. Oclacitinib provides itch relief within 24 h that persistes through the treatment period, with over 70% of the treated dogs achieving a >50% reduction in pruritus by day 7[2]. |
| Alias | PF-03394197 maleate, PF-03394197 |
| Molecular Weight | 453.51 |
| Formula | C15H23N5O2S·C4H4O4 |
| Cas No. | 1640292-55-2 |
| Smiles | OC(=O)\C=C\C(O)=O.CNS(=O)(=O)C[C@H]1CC[C@@H](CC1)N(C)c1ncnc2[nH]ccc12 |
| Relative Density. | no data available |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||||||||||||
| Solubility Information | H2O: 15 mg/mL (33.08 mM), Sonication is recommended. Ethanol: 83 mg/mL (183.02 mM), Sonication is recommended. DMSO: 83 mg/mL (183.02 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||||||||||||
H2O/Ethanol/DMSO
Ethanol/DMSO
| |||||||||||||||||||||||||||||||||||||||||
Sci Citations
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy Oclacitinib maleate | purchase Oclacitinib maleate | Oclacitinib maleate cost | order Oclacitinib maleate | Oclacitinib maleate chemical structure | Oclacitinib maleate in vivo | Oclacitinib maleate in vitro | Oclacitinib maleate formula | Oclacitinib maleate molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.